ArticleFrontiers in medicine2024
Longitudinal antinuclear antibody titers in systemic lupus erythematosus and other rheumatic diseases.
Article in Frontiers in medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The 2026 British Society for Rheumatology guideline for the management of children, young people and adults with systemic lupus erythematosus.Rheumatology (Oxford, England) · 2026Guideline
- Diagnostic Value of ANA Titer, Anti-ds-DNA, Anti-nRNPSm, and Sm Antibodies in Early Atypical Systemic Lupus Erythematosus.Pakistan journal of medical sciences · 2026Article
- Characterization of Dendritic Cells and Myeloid-Derived Suppressor Cells Expressing Major Histocompatibility Complex Class II in Secondary Lymphoid Organs in Systemic Lupus Erythematosus-Prone Mice.International journal of molecular sciences · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Introduction: Antinuclear antibodies (ANAs) are a key feature of systemic lupus erythematosus (SLE) and marker of subclinical autoimmunity. Little is known about longitudinal ANA titers in individuals from the general population or in predicting clinical disease course in persons with rheumatic diseases. Methods: We performed an exploratory analysis from an academic health system between 1999 and 2020 to assess intra-individual variation in ANAs longitudinally in persons with SLE, other ANA-associated rheumatic diseases, and ANA+ controls without rheumatic disease. Results: Persons with SLE had a higher odds of positive ANA compared to those with other ANA-associated rheumatic diseases [OR 2.10, 95% CI (1.82, 2.43)] controlling for time and demographics (age, sex, race, ethnicity). Compared to ANA+ controls, the ANA titer strength was significantly higher for both the ANA-associated rheumatic disease (0.33 log units higher) and SLE groups (0.42 log units higher) controlling for demographics and time ( Conclusion: Based on this analysis of electronic health data spanning two decades, ANA titers may be more dynamic than previously accepted in patients with SLE and ANA-associated rheumatic diseases, with average titers tending to be higher in early disease and decreasing over time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.